Consider chemotherapy early to increase mCRPC survival
February 12, 2015|Hematology and Oncology
Author and Disclosure Information
EXPERT ANALYSIS FROM ICACT 2015
“We need to think about the sequence of treatment as early as possible,” Dr. Oudard concluded. Considering the CHAARTED study findings, he added: “We maybe need to propose chemotherapy much earlier” in order to overcome resistance. “The difference in using docetaxel much earlier is huge in terms of overall survival outcome.”
Dr. Oudard has consulting agreements with Bayer, GSK, Janssen, Keocyt, Novartis, Pfizer, Roche, Sanofi, and Takeda.
